A Case of Acute Promyelocytic Leukemia after Iodine-131 Treatment for Thyroid Cancer.
10.5045/kjh.2006.41.4.302
- Author:
Sang Hun LEE
1
;
Ki Seong EOM
;
Seok LEE
;
Hee Je KIM
;
Chang Ki MIN
;
Sung Yong KIM
;
Byung Sik CHO
;
Hyuk LEE
;
Chan Kwon PARK
;
Seok Goo CHO
;
Dong Wook KIM
;
Jong Wook LEE
;
Woo Sung MIN
;
Chun Choo KIM
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea. dreom@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Acute promyelocytic leukemia;
Radioactive iodine;
Secondary AML
- MeSH:
Follow-Up Studies;
Humans;
Iodine;
Leukemia;
Leukemia, Promyelocytic, Acute*;
Thyroid Gland*;
Thyroid Neoplasms*;
Thyroidectomy
- From:Korean Journal of Hematology
2006;41(4):302-305
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Radioactive iodine (131I) has been used in the treatment of thyroid cancer to eliminate residual thyroid tissue after thyroidectomy and to treat metastatic disease. Leukemia has rarely been reported as a late complication of 131I therapy, occurring most frequently after receiving a cumulative activity of 800 mCi of the radioisotope. Although FAB M3 type (acute promyelocytic leukemia, APL) as the secondary acute leukemia had been rarely reported, recently there have been a few cases of therapy-related APL leukemia seen. We hereby report a case of secondary acute promyelocytic leukemia occurring in a patient who received radioactive iodine therapy for papillary thyroid carcinoma. An assessment of causality using the Naranjo probability scale showed that a possible relationship existed between APL seen in the patient and the use of the radioactive iodine. Although this is a very rare event, strict hematologic follow-up of patients treated with radioactive iodine may be warranted, along with a high index of suspicion in those with coagulopathy.
